Arcus Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Arcus Biosciences Inc in the second quarter 2026?
Arcus Biosciences Inc recorded a cumulative net loss of $-460 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -89.54%.

Within the Major Pharmaceutical Preparations industry 242 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2006 to 3402.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-15.48 %	-1.32 %	30.1 %	-22.83 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-460	-369	-353	-341	-298
Return On Equity (TTM)	-89.54 %	-68.97 %	-65.77 %	-68.17 %	-55.96 %
RCUS's Total Ranking	# 3402	# 2006	# 2235	# 3115	#
Equity (TTM) in Millions	464	524	631	436	549
Seq. Equity Change	-11.45 %	-16.96 %	44.72 %	-20.58 %	3.39 %
Seq. Net Income Change	-	-	-	-	-

Back to RCUS Management Effectiveness >> RCUS's 5 Years Annual ROE >> Compare RCUS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 243
Sector	# 533
Overall	# 3402

Return On Equity Statistics
High	Average	Low
10.35 %	-40.36 %	-89.54 %
(Sep 30 2022)		(Jun 30 2026)

News about Arcus Biosciences Inc Return on Equity ROE

Arcus Biosciences Reports Strong Q3 2024 Financials and Breakthroughs in Cancer Therapies, Highlighting Promising C...

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Pipeline Momentum in Cancer Therapies HAYWARD, Calif. In a recent announcement, Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company committed to developing innovative therapies for cancer treatment, reported its financial results for the third quarter ended September 30, 2024. The results underscore the company s ongoing dedication to advancing its robust pipeline of investigational molecules designed to address multiple cancers through targeted approaches. Financial Highlights for Q3 2024In the third quarter of 2024, Arcus Biosciences demonstrated solid financial performance, reflecting both the progress of its clinical programs and its sustained financial health amidst dynamic market conditions. The reported figures indicate advancements in research and clinical development investments. While the specific financial numbers are not detailed in the press release, the company emphasized that they remain on track to achieve both short-term and long-term operational goals, crucial for sustaining their innovative projects.

Arcus Biosciences Weathering Financial Storms While Pioneering Tomorrow’s Cancer Therapies,

Hayward, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a pioneering clinical-stage biopharmaceutical company committed to combating cancer with innovative molecules and combination therapies, has released its financial results for the third quarter of 2024. The results indicate significant developments, both financially and in clinical advancements, as the company continues its strategic endeavor to improve patient outcomes across a range of malignancies.For the quarter ending September 30, 2024, Arcus reported a cumulative net loss of $249 million over the twelve months leading up to Q2 2024, translating to a disappointing return on equity (ROE) of -42.86%. This figure highlights the inherent risks involved with early-stage biopharmaceutical companies as they progress through the clinical trial landscape. The sector remains competitive, with 141 other companies in the Major Pharmaceutical Preparations industry showcasing a higher ROE during this period.

RCUS Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	631	485	462	657	841
Y / Y Equity Change	30.1 %	4.98 %	-29.68 %	-21.92 %	67.52 %
Net Income in Millions	-353	-283	-307	-267	53
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-55.94 %	-58.35 %	-66.45 %	-40.64 %	6.28 %

Back to RCUS Management Effectiveness >> RCUS's 5 Years Annual ROE >> Compare RCUS ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RCUS's' Return on Equity at Yahoo Finance
RCUS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RCUS's Competitors
Subscribers only: Roe for Arcus Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for RCUS's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.